Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV)

Addiction Biology

Volumn 19, Issue 2, 2014, Pages 165-174

  Watterson, Lucas R ^a   Kufahl, Peter R ^a   Nemirovsky, Natali E ^a   Sewalia, Kaveish ^a   Grabenauer, Megan ^b   Thomas, Brian F ^b   Marusich, Julie A ^b   Wegner, Scott ^a   Olive, M Foster ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b RTI INTERNATIONAL   (United States)

Author keywords

4 methylenedioxypyrovalerone; abuse liability; bath salt; extended access; intracranial self stimulation; intravenous self administration; synthetic cathinone

Indexed keywords

1,3 BENZODIOXOLE DERIVATIVE; 3,4-METHYLENEDIOXYPYROVALERONE; CENTRAL STIMULANT AGENT; DESIGNER DRUG; METHAMPHETAMINE; PYRROLIDINE DERIVATIVE;

ADDICTION; ANALYSIS OF VARIANCE; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; DRUG SEEKING BEHAVIOR; DRUG SELF ADMINISTRATION; ELECTROSTIMULATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; PROCEDURES; PSYCHOLOGY; RAT; REINFORCEMENT; REWARD; SELF STIMULATION; SPRAGUE DAWLEY RAT; STATISTICS AND NUMERICAL DATA; TIME;

ANALYSIS OF VARIANCE; ANIMALS; BENZODIOXOLES; CENTRAL NERVOUS SYSTEM STIMULANTS; DESIGNER DRUGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-SEEKING BEHAVIOR; ELECTRIC STIMULATION; INFUSIONS, INTRAVENOUS; MALE; METHAMPHETAMINE; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; REINFORCEMENT (PSYCHOLOGY); REINFORCEMENT SCHEDULE; REWARD; SELF ADMINISTRATION; SELF STIMULATION; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

EID: 84894430078     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2012.00474.x     Document Type: Article

References (40)

1. Ahmed S, (2011) Escalation of drug use. In:, Olmstead MC, ed. Animal Models of Drug Addiction, pp. 267-292. Totowa, NJ: Humana Press.
2. Ahmed SH, Koob GF, (1998) Transition from moderate to excessive drug intake: change in hedonic set point. Science 282: 298-300.
3. American Psychiatric Association (2004) Diagnostic and Statistical Manual of Mental Disorders, DSM-IV-TR. Washington, DC: American Psychiatric Press.
4. Collins RJ, Weeks JR, Cooper MM, Good PI, Russell RR, (1983) Prediction of abuse liability of drugs using IV self-administration by rats. Psychopharmacology (Berl) 82: 6-13.
5. Coppola M, Mondola R, (2012) 3,4-Methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett 208: 12-15.
6. Deniker P, Loo H, Cuche H, Roux JM, (1975) Abuse of pyrovalerone by drug addicts. Ann Med Psychol 2: 745-748.
7. Drug Enforcement Administration (2011a) Background, Data and Analysis: Mephedrone (4-MMC), Methylone (MDMC) and 3,4-Methylenedioxypyrovalerone (MDPV). Washington, DC: United States Department of Justice, Office of Drug Control, Drug and Chemical Evaluation Section.
8. Drug Enforcement Administration (2011b) Schedules of controlled substances: temporary placement of three synthetic cathinones into Schedule I. United States Department of Justice, Federal Register, 21 CFR Part 1308, Docket No. DEA-357, Washington, DC.
9. Durham M, (2011) Ivory wave: the next mephedrone. Emerg Med J 28: 1059-1060.
10. Esposito R, Motola A, Kornetsky C, (1978) Cocaine: acute effects on reinforcement thresholds for self-stimulation behavior to the medial forebrain bundle. Pharmacol Biochem Behav 8: 437-439.
11. Fuwa W, Kodama T, Honda Y, Tanaka Y, Kubo Y, Ohashi N, Nakae N, Ogat A, (2009) CNS effects of methylenedioxypyrovalerone using microdialysis. Integr Manag Biol Chem 9: 62-72.
12. Gass JT, Osborne M, Watson NL, Brown JL, Olive MF, (2009) mGluR5 antagonism attenuates methamphetamine reinforcement and prevents reinstatement of methamphetamine-seeking behavior in rats. Neuropsychopharmacology 34: 820-833.
13. Gipson CD, Bardo MT, (2009) Extended access to amphetamine self-administration increases impulsive choice in a delay discounting task in rats. Psychopharmacology (Berl) 207: 391-400.
14. Goldberg J, Gardos G, Cole JO, (1973) A controlled evaluation of pyrovalerone in chronically fatigued volunteers. Int Pharmacopsychiatry 8: 60-69.
15. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM, Hoonakker AJ, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE, (2011) 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339: 530-536.
16. Holliday AR, Morris RB, Sharpley RP, (1964) Compound 84/F 1983 compared with d-amphetamine and placebo in regard to effects on human performance. Psychopharmacologia 6: 192-200.
17. Horovitz ZP, Chow MI, Carlton PL, (1972) Effects of d-amphetamine, scopolamine, chlordiazepoxide and diphenylhydantoin on self-stimulation behavior and brain acetylcholine. Psychopharmacologia 3: 1-16.
18. Kavanagh P, McNamara S, Angelov D, McDermott S, Mullan D, Ryder S, (2011) The characterization of 'legal highs' available from head shops in Dublin. Available at: http://addictionireland.com/-fileupload/publications/Legal-Highs- Poster.pdf. Accessed 21 February 2012.
19. Kelly JP, (2011) Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test Anal 3: 439-453.
20. Kitamura O, Wee S, Specio S, Koob G, (2006) Escalation of methamphetamine self-administration in rats: a dose-effect function. Psychopharmacology (Berl) 186: 48-53.
21. Kornetsky C, Bain G, (1992) Brain-stimulation reward: a model for the study of the rewarding effects of abused drugs. NIDA Res Monogr 124: 73-93.
22. Kornetsky C, Esposito RU, McLean S, Jacobson JO, (1979) Intracranial self-stimulation thresholds: a model for the hedonic effects of drugs of abuse. Arch Gen Psychiatry 36: 289-292.
23. Lancelot JC, Robba M, Bonnett JJ, Vaugeois JM, Costentin J, (1992) Synthetic and preliminary study of the activity of thiophene analogues of pyrovalerone on the neuronal uptake of the monoamines. Eur J Med Chem 27: 297-300.
24. Magdum SS, (2011) An overview of khat. Addict Disord Treat 10: 72-83.
25. Markou A, Koob GF, (1992) Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. Physiol Behav 51: 111-119.
26. Marusich JA, Blough BE, Wiley JL, (2011) Effects of 'bath salts' and other novel dopamine and serotonin agonist on overt behaviors in rodents. Program No. 571.02. 2011 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2011. Online.
27. Meisch RA, (1987) Factors controlling drug reinforced behavior. Pharmacol Biochem Behav 27: 367-371.
28. Meltzer PC, Butler D, Deschamps JR, Madras BK, (2006) 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem 49: 1420-1432.
29. Olds J, Milner P, (1954) Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J Comp Physiol Psychol 47: 419-427.
30. Panlilio LV, (2011) Stimulant self-administration. In:, Olmstead MC, ed. Animal Models of Drug Addiction, pp. 57-82. Totowa, NJ: Humana Press.
31. Psychonaut WebMapping Research Group (2009a) Mephedrone Report. London, UK: Institute of Psychiatry, King's College London. Available at: http://www.psychonautproject.eu/documents/reports/Mephedrone.pdf. Accessed 21 February 2012.
32. Psychonaut WebMapping Research Group (2009b) MDPV Report. London, UK: Institute of Psychiatry, King's College London. Available at: http://www.psychonautproject.eu/documents/reports/MDPV.pdf. Accessed 21 February 2012.
33. Richardson N, Roberts D, (1996) Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods 66: 1-11.
34. Roberts DC, Loh EA, Vickers G, (1989) Self-administration of cocaine on a progressive ratio schedule in rats: dose-response relationship and effect of haloperidol pretreatment. Psychopharmacology (Berl) 97: 535-538.
35. Sarkar M, Kornetsky C, (1995) Methamphetamine's action on brain-stimulation reward threshold and stereotypy. Exp Clin Psychopharmacol 3: 112-117.
36. Spiller HA, Ryan ML, Weston RG, Jansen J, (2011) Clinical experience with and analytical confirmation of 'bath salts' and 'legal highs' (synthetic cathinones) in the United States. Clin Toxicol 49: 499-505.
37. Vardakou I, Pistos C, Spiliopoulou C, (2010) Drugs for youth via Internet and the example of mephedrone. Toxicol Lett 201: 191-195.
38. Vlachou S, Markou A, (2011) Intracranial self-stimulation. In:, Olmstead MC, ed. Animal Models of Drug Addiction, pp. 3-56. Totowa, NJ: Humana Press.
39. Wise RA, (1996) Addictive drugs and brain stimulation reward. Annu Rev Neurosci 19: 319-340.
40. Yohannan JC, Bozenko JS, (2010) The characterization of 3,4-methylenedioxypyrovalerone (MDPV). Microgram J 7: 5-15.